Caladrius Bioscience To Start Testing Its CD34+ Cell Therapy in Diabetic Kidney Disease

by Vandana Singh, Benzinga Editor
June 22, 2021 10:51 AM | 22 seconds read |
  • The FDA has signed off Caladrius Bioscience Inc's CLBS investigational new drug application for the study of CLBS201 for the treatment of diabetic kidney disease ("DKD").
  • The company plans to initiate a Phase 1/2 proof-of-concept study of CLBS201 within the next several months. 
  • Price Action: CLBS shares are up 0.06% at $1.56 during the market session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Comments
Posted In: BiotechNewsPenny StocksHealth CareFDAGeneralBriefsKidney Diseases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga

© 2024 Benzinga | All Rights Reserved